Cannabinoids as an Emerging Therapy for Posttraumatic Stress Disorder and Substance Use Disorders

Jacob Cohen; Zelan Wei; Jonathan Phang; Robert B. Laprairie; Yanbo Zhang

doi:10.1097/WNP.0000000000000612

Cannabinoids as an Emerging Therapy for Posttraumatic Stress Disorder and Substance Use Disorders

Jacob Cohen, Zelan Wei, Jonathan Phang, Robert B. Laprairie, Yanbo Zhang

Medicine

Research output: Contribution to journal › Review article › peer-review

9 Citations (Scopus)

Abstract

Posttraumatic Stress Disorder (PTSD) is a leading psychiatric disorder that mainly affects military and veteran populations but can occur in anyone affected by trauma. PTSD treatment remains difficult for physicians because most patients with PTSD do not respond to current pharmacological treatment. Psychotherapy is effective, but time consuming and expensive. Substance use disorder is often concurrent with PTSD, which leads to a significant challenge for PTSD treatment. Cannabis has recently received widespread attention for the potential to help many patient populations. Cannabis has been reported as a coping tool for patients with PTSD and preliminary legalization data indicate Cannabis use may reduce the use of more harmful drugs, such as opioids. Rigorous clinical studies of Cannabis could establish whether Cannabis-based medicines can be integrated into treatment regimens for both PTSD and substance use disorder patients.

Original language	English
Pages (from-to)	28-34
Number of pages	7
Journal	Journal of Clinical Neurophysiology
Volume	37
Issue number	1
DOIs	https://doi.org/10.1097/WNP.0000000000000612
Publication status	Published - Jan 1 2020

Bibliographical note

Funding Information:
J. Cohen is supported by Department of Psychiatry Intramural Awards, Kripa Thaur Memorial Award, Royal Canadian Legion Bursary, and MITACS Accelerate Master’s Fellowship. R. B. Laprairie is supported by a partnership char from GlaxoSmithKline and the Canadian Institutes of Health Research, and grants from the College of Pharmacy and Nutrition, NSERC, and the Saskatchewan Health Research Foundation. Y. Zhang is supported by the Iver and Joyce Graham Indiana Small Professorship, and grants from the Department of psychiatry and the College of Medicine, and the Saskatchewan Health Research Foundation. The authors have no conflicts of interest to disclose.

Publisher Copyright:
© 2019 by the American Clinical Neurophysiology Society.

ASJC Scopus Subject Areas

Physiology
Neurology
Clinical Neurology
Physiology (medical)

Access to Document

10.1097/WNP.0000000000000612

Cite this

@article{4a90429233304b4e8c0e1668476a4dfc,

title = "Cannabinoids as an Emerging Therapy for Posttraumatic Stress Disorder and Substance Use Disorders",

abstract = "Posttraumatic Stress Disorder (PTSD) is a leading psychiatric disorder that mainly affects military and veteran populations but can occur in anyone affected by trauma. PTSD treatment remains difficult for physicians because most patients with PTSD do not respond to current pharmacological treatment. Psychotherapy is effective, but time consuming and expensive. Substance use disorder is often concurrent with PTSD, which leads to a significant challenge for PTSD treatment. Cannabis has recently received widespread attention for the potential to help many patient populations. Cannabis has been reported as a coping tool for patients with PTSD and preliminary legalization data indicate Cannabis use may reduce the use of more harmful drugs, such as opioids. Rigorous clinical studies of Cannabis could establish whether Cannabis-based medicines can be integrated into treatment regimens for both PTSD and substance use disorder patients.",

author = "Jacob Cohen and Zelan Wei and Jonathan Phang and Laprairie, {Robert B.} and Yanbo Zhang",

note = "Funding Information: J. Cohen is supported by Department of Psychiatry Intramural Awards, Kripa Thaur Memorial Award, Royal Canadian Legion Bursary, and MITACS Accelerate Master{\textquoteright}s Fellowship. R. B. Laprairie is supported by a partnership char from GlaxoSmithKline and the Canadian Institutes of Health Research, and grants from the College of Pharmacy and Nutrition, NSERC, and the Saskatchewan Health Research Foundation. Y. Zhang is supported by the Iver and Joyce Graham Indiana Small Professorship, and grants from the Department of psychiatry and the College of Medicine, and the Saskatchewan Health Research Foundation. The authors have no conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2019 by the American Clinical Neurophysiology Society.",

year = "2020",

month = jan,

day = "1",

doi = "10.1097/WNP.0000000000000612",

language = "English",

volume = "37",

pages = "28--34",

journal = "Journal of Clinical Neurophysiology",

issn = "0736-0258",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Cannabinoids as an Emerging Therapy for Posttraumatic Stress Disorder and Substance Use Disorders

AU - Cohen, Jacob

AU - Wei, Zelan

AU - Phang, Jonathan

AU - Laprairie, Robert B.

AU - Zhang, Yanbo

N1 - Funding Information: J. Cohen is supported by Department of Psychiatry Intramural Awards, Kripa Thaur Memorial Award, Royal Canadian Legion Bursary, and MITACS Accelerate Master’s Fellowship. R. B. Laprairie is supported by a partnership char from GlaxoSmithKline and the Canadian Institutes of Health Research, and grants from the College of Pharmacy and Nutrition, NSERC, and the Saskatchewan Health Research Foundation. Y. Zhang is supported by the Iver and Joyce Graham Indiana Small Professorship, and grants from the Department of psychiatry and the College of Medicine, and the Saskatchewan Health Research Foundation. The authors have no conflicts of interest to disclose. Publisher Copyright: © 2019 by the American Clinical Neurophysiology Society.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Posttraumatic Stress Disorder (PTSD) is a leading psychiatric disorder that mainly affects military and veteran populations but can occur in anyone affected by trauma. PTSD treatment remains difficult for physicians because most patients with PTSD do not respond to current pharmacological treatment. Psychotherapy is effective, but time consuming and expensive. Substance use disorder is often concurrent with PTSD, which leads to a significant challenge for PTSD treatment. Cannabis has recently received widespread attention for the potential to help many patient populations. Cannabis has been reported as a coping tool for patients with PTSD and preliminary legalization data indicate Cannabis use may reduce the use of more harmful drugs, such as opioids. Rigorous clinical studies of Cannabis could establish whether Cannabis-based medicines can be integrated into treatment regimens for both PTSD and substance use disorder patients.

AB - Posttraumatic Stress Disorder (PTSD) is a leading psychiatric disorder that mainly affects military and veteran populations but can occur in anyone affected by trauma. PTSD treatment remains difficult for physicians because most patients with PTSD do not respond to current pharmacological treatment. Psychotherapy is effective, but time consuming and expensive. Substance use disorder is often concurrent with PTSD, which leads to a significant challenge for PTSD treatment. Cannabis has recently received widespread attention for the potential to help many patient populations. Cannabis has been reported as a coping tool for patients with PTSD and preliminary legalization data indicate Cannabis use may reduce the use of more harmful drugs, such as opioids. Rigorous clinical studies of Cannabis could establish whether Cannabis-based medicines can be integrated into treatment regimens for both PTSD and substance use disorder patients.

UR - http://www.scopus.com/inward/record.url?scp=85077392004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077392004&partnerID=8YFLogxK

U2 - 10.1097/WNP.0000000000000612

DO - 10.1097/WNP.0000000000000612

M3 - Review article

C2 - 31895187

AN - SCOPUS:85077392004

SN - 0736-0258

VL - 37

SP - 28

EP - 34

JO - Journal of Clinical Neurophysiology

JF - Journal of Clinical Neurophysiology

IS - 1

ER -

Cannabinoids as an Emerging Therapy for Posttraumatic Stress Disorder and Substance Use Disorders

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this